Medical Condition News

RSS

Patients with VAD implants develop varying severities of AVWS

The findings of a 12 patient study recently published in Thrombosis and Haemostasis by University Medical Center Freiburg documented that patients implanted with a ventricular assist device (VAD) experienced a rapid onset of acquired von Willebrand syndrome (AVWS), while patients implanted with the SynCardia temporary Total Artificial Heart did not.

21 May 2010

Data on retreatment experiences with brentuximab vedotin in clinical trials to be presented at 2010 ASCO

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company today announced that data regarding retreatment experiences with brentuximab vedotin in phase I and phase II clinical trials will be presented during a poster session at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8, 2010 in Chicago, Illinois.

21 May 2010

Study explores genetic imbalances that give rise to childhood brain tumors

The most comprehensive analysis yet of the genetic imbalances at the heart of childhood brain tumors known as high-grade gliomas (HGGs) identified a cancer gene that is unusually active in some tumors and is now the focus of a St. Jude Children's Research Hospital clinical trial.

21 May 2010

PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in hematology and oncology, today announced that clinical data on belinostat will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology, to be held June 4-8, 2010 at the McCormick Place Convention Center in Chicago, Illinois, as part of the ASCO proceedings.

21 May 2010

Combination of reovirus and carboplatin/paclitaxel shows promising anticancer activity in SCCHN

Oncolytics Biotech Inc. announced today that abstracts covering clinical research with reovirus (REOLYSIN(R)) are available on the American Society of Clinical Oncology website at www.asco.org, and on the Oncolytics website at www.oncolyticsbiotech.com.

21 May 2010

Interim data from Phase 2 clinical trial of sapacitabine in patients with MDS to be presented at ASCO 2010

Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.

21 May 2010

New therapy program serves as foundation for ongoing clinical development

The researchers of the University of Helsinki, and Oncos Therapeutics, the biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published initial results from their Advanced Therapy Access Program in Cancer Research.

21 May 2010

Cancer Institute of New Jersey investigators target autophagy

In an effort to improve current anticancer treatments, investigators at The Cancer Institute of New Jersey (CINJ) have been targeting a process known as autophagy, in which cancer cells eat themselves as a measure of self preservation under chemotherapy and radiation stress, thus prolonging tumor cell survival and inducing resistance to therapy.

21 May 2010

Blood biomarker underscores role of inflammation in vascular disease

UC Davis researchers have discovered that a blood component linked with inflammation can predict coronary artery disease in African-Americans.

21 May 2010

Smoking cessation treatments effective and safe for people with schizophrenia

In a study published today in the journal Addiction, researchers have determined that treatment for smoking dependence is as effective among people with severe mental illnesses as it is for the general population. Importantly, they also found that offering such treatments does not appear to cause deterioration in mental health.

21 May 2010

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Abraxis BioScience, Inc., a fully integrated biotechnology company, previously announced it will be presenting more than 30 studies, including new clinical data evaluating the use of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable suspension; paclitaxel protein albumin-bound particles for injectable suspension) for the treatment of pancreatic cancer at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

SAMHSA study reveals differences in rates of substance use among various Asian-American adults

A new national study by the Substance Abuse and Mental Health Services Administration (SAMHSA) shows there are significant differences in rates of substance use among adults in various Asian-American populations. For example, the past month binge drinking rate among Korean-American adults is three times higher than among Chinese-American adults (25.9 percent versus 8.4 percent). Similarly the level of past month illicit drug use among Japanese-American adults is nearly three times higher than the level among Asian Indian-American adults.

21 May 2010

Pluristem to highlight potential of PLX-PAD cell therapy for critical limb ischemia at 16th ISCT

Pluristem Therapeutics Inc. today announced that its off-the-shelf placenta-derived cell therapies will be the focus of presentations at upcoming investor and medical conferences.

21 May 2010

Researchers propose steps to enhance patient-physician communication to improve depression care

Because people with depression often do not recognize they have a problem or are unable to describe their distress, many do not seek treatment. About a quarter of those with major depression are undiagnosed, according to several studies, and fewer than half receive treatment.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Group weight loss programs reduce risk for type 2 diabetes

The 57 million Americans currently living with "pre-diabetes" could benefit from a group weight loss program, like Weight Watchers, according to a new study published in this month's American Journal of Lifestyle Medicine. Researchers found that after a 6-month Weight Watchers group program, overweight or obese adults who attended at least two thirds of the weekly sessions, not only lost weight, but also significantly reduced fasting glucose and insulin levels - important indicators of diabetes risk.

21 May 2010

Researchers identify drug that improves communication between nerve cells in Phelan-McDermid Syndrome

Researchers from Mount Sinai School of Medicine have identified a drug that improves communication between nerve cells in a mouse model of Phelan-McDermid Syndrome (PMS). Behavioral symptoms of PMS fall under the autism spectrum disorder category. The research will be presented Friday at the International Meeting for Autism Research (IMFAR) in Philadelphia.

21 May 2010

Psychiatrists should be included in disaster first-response teams

Psychiatrists should be included in disaster first-response teams because survivors have immediate need for help in alleviating early trauma symptoms ranging from sleeplessness to constant anxiety, says a new study of 9/11 survivors and victims' family members published today in the Journal of Psychiatric Practice.

21 May 2010

Researchers discover key gene that promotes development of common kidney cancer

Researchers at Mayo Clinic's campus in Florida have discovered a key gene that, when turned off, promotes the development of common kidney cancer. Their findings suggest that a combination of agents now being tested in other cancers may turn the gene back on, providing a much-needed therapy for the difficult-to-treat cancer.

21 May 2010

Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has announced further positive data on the first forty subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma, with an objective response ("OR") observed in 61% of subjects and a mean Progression Free Survival ("PFS") of at least 11.1 months among those subjects achieving an OR.

21 May 2010

Medical Condition News

Patients with VAD implants develop varying severities of AVWS

Data on retreatment experiences with brentuximab vedotin in clinical trials to be presented at 2010 ASCO

Study explores genetic imbalances that give rise to childhood brain tumors

PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting

Combination of reovirus and carboplatin/paclitaxel shows promising anticancer activity in SCCHN

Interim data from Phase 2 clinical trial of sapacitabine in patients with MDS to be presented at ASCO 2010

New therapy program serves as foundation for ongoing clinical development

Cancer Institute of New Jersey investigators target autophagy

Blood biomarker underscores role of inflammation in vascular disease

Smoking cessation treatments effective and safe for people with schizophrenia

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

SAMHSA study reveals differences in rates of substance use among various Asian-American adults

Pluristem to highlight potential of PLX-PAD cell therapy for critical limb ischemia at 16th ISCT

Researchers propose steps to enhance patient-physician communication to improve depression care

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Group weight loss programs reduce risk for type 2 diabetes

Researchers identify drug that improves communication between nerve cells in Phelan-McDermid Syndrome

Psychiatrists should be included in disaster first-response teams

Researchers discover key gene that promotes development of common kidney cancer

Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Latest News